Icahn's $5.4 Bil. Bid For Mylan Leaves Door Open To A "White Knight" Suitor

Investor offers $20 per share, a 17% premium over Mylan's closing price a day earlier. Icahn suggests other pharma companies are potentially interested in buying the generic drug maker and is proposing an acquisition contract with no break-up fee so that Mylan could pursue other offers.